Clinical Trial

A Study to Evaluate the Efficacy and Safety of KarXT in Acutely Psychotic Japanese Adult Participants With Schizophrenia

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the efficacy and safety of KarXT in acutely psychotic Japanese adult participants with schizophrenia
Protocol Amendment History 18 amendments
This ClinicalTrials.gov record has been amended 18 times since 2025-03-17; most recent amendment 2026-06-29.
Status change: Not Yet Recruiting → Recruiting 2025-06-17
Trial Details
NCT Number NCT06882785
Lead Sponsor Bristol-Myers Squibb
Conditions Schizophrenia
Enrollment 250 participants
Start Date 2025-06-10
Primary Completion 2028-09-23 (estimated)
Study Completion 2029-08-23 (estimated)
Updated on ClinicalTrials.gov 2026-07-27